Key Points Rhythm Pharmaceuticals' lone approved product currently generates minimal sales.However, recent clinical progress ...

The global fight between Eli Lilly and Novo Nordisk for dominance in the red-hot weight-loss drug market is shifting to India, one of the fastest-growing pharmaceutical frontiers. As rising ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and ...